Practice

Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access

December 22nd 2024

By Skylar Jeremias

Article

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.

13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching

December 18th 2024

By Skylar Jeremias

Article

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.

Study Shows Biosimilarity of Bevacizumab Biosimilar in CRC

December 17th 2024

By Skylar Jeremias

Article

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) in patients with metastatic colorectal cancer (CRC).

Strategies for Improving Biosimilar Access and Utilization

December 15th 2024

By Skylar Jeremias

Video

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discussed barriers to biosimilar adoption and highlighted strategies such as physician education, streamlined implementation, payer collaboration, and patient engagement to improve access, reduce costs, and enhance adherence to biologic therapies.

AI-Powered Solutions for Streamlining Biosimilar Prescribing and Monitoring

December 8th 2024

By Skylar Jeremias

Video

Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and generics, enhance provider engagement, and improve pharmacovigilance by tracking adoption rates and identifying potential issues.

Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts

December 4th 2024

By Skylar Jeremias

Article

Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.

How Early Adopters Are Shaping the Future of Biosimilars

November 24th 2024

By Skylar Jeremias

Article

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and cost savings.

Webinar: Streamlining the Regulatory Process to Advance Access to Biosimilars

November 21st 2024

By The Center for Biosimilars Staff

Video

This webinar celebrating Global Biosimilars Week was hosted by The Center for Biosimilars® in partnership with the International Generics and Biosimilars Association.

Boosting Health Care Sustainability: The Role of Biosimilars in Latin America

November 21st 2024

By Skylar Jeremias

Article

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.

Breaking Down Biosimilar Barriers: Payer and PBM Policies

November 13th 2024

By Skylar Jeremias

Article

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.